[Form 4/A] ASTRONICS CORP Amended Insider Trading Activity
Rhea-AI Filing Summary
Astronics Corp. (ATRO) President and CEO Peter J. Gundermann reported multiple equity transactions dated 11/20/2025. He exercised stock options to acquire 13,700 shares of $.01 par value common stock and 4,418 shares of $.01 par value Class B stock at an exercise price of $27.72 per share. To cover withholding taxes tied to the option exercise, 11,707 common shares were withheld at a price of $49.35 per share. Following these transactions, he directly owned 83,906.608 common shares and 747,911 Class B shares.
The filing also lists outstanding equity awards. These include multiple stock option grants with exercise prices ranging from $9.74 to $35.61 per share and expirations between 12/03/2025 and 12/07/2033, as well as several restricted stock unit awards tied to Astronics’ average annual adjusted EBITDA performance for periods running from 2023–2027, with potential vesting ranges between 50% and 150% of target on future dates.
Positive
- None.
Negative
- None.
FAQ
What insider transaction did Astronics (ATRO) report for 11/20/2025?
The President and CEO exercised options for 13,700 common shares and 4,418 Class B shares at $27.72 per share and had 11,707 common shares withheld to cover taxes.
How many Astronics (ATRO) shares does the CEO hold after the reported transactions?
After the 11/20/2025 transactions, the CEO directly owned 83,906.608 shares of common stock and 747,911 shares of Class B stock.
What stock option grants for Astronics (ATRO) are listed in this Form 4/A?
The filing lists several stock options on Astronics common and Class B stock with exercise prices between $9.74 and $35.61 per share and expirations from 12/03/2025 to 12/07/2033.
How are Astronics (ATRO) restricted stock units structured for the CEO?
Each restricted stock unit represents the right to receive one common share at settlement, with vesting based on Astronics’ average annual adjusted EBITDA over specified multi-year periods.
What performance periods affect Astronics (ATRO) EBITDA-based RSU vesting?
EBITDA-based RSUs depend on average annual adjusted EBITDA for periods 2023–2025, 2024–2026, and 2025–2027, with vesting dates in 2026, 2027, and 2028.
What are the potential vesting ranges for Astronics (ATRO) performance RSUs?
Depending on actual EBITDA performance, between 75% and 115% of target units may vest for the 2023–2025 award, and between 50% and 150% of target units may vest for the 2024–2026 and 2025–2027 awards.